节点文献

托吡酯添加治疗难治性癫癎的有效性和安全性

Efficacy and safty of Topiramate as adjunctive therapy for refractory epileptic patients

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 杨少青廖卫平潘英王延平易咏红黎冰梅何小诗邓宇虹刘晓蓉方敏华

【Author】 YANG Shao-qing,LIAO Wei-ping,PAN Ying,et al.Institute of Neuroscience and Second Affiliated Hospital of Guangzhou Medical College,Guangzhou 510260,China

【机构】 广州医学院第二附属医院暨神经科学研究所广州医学院第二附属医院暨神经科学研究所 510260510260

【摘要】 目的探讨托吡酯添加治疗难治性癫疒间的有效性和安全性。方法对115例难治性癫疒间患者应用托吡酯小剂量逐渐添加的开放性自身对照研究,第8周达最大耐受量后维持1~3年或以上。评定托吡酯的长期疗效、安全性及其与剂量的关系。结果治疗第8周、6个月、1年、2年和3年发作频率减少百分比的中位数:成人分别为56.0%、75.8%、76.1%、77.3%、78.1%,儿童分别为32.1%、66.7%、68.9%、70.1%、70.8%。部分性发作的有效率(70.6%)高于全面性发作(37.5%,P<0.05),其中10例(11.3%)无发作>2年。有效组维持剂量成人为(129.3±54.3)mg/d,儿童为(3.1±1.4)mg/(kg.d)。1年、2年及3年托吡酯保留率分别为72.2%、62.5%和56.1%。33例(28.7%)出现不良反应,大部分出现在加量期,最常见的为胃纳差。因不良反应退出6例(8.2%),因疗效不佳退出16例(21.9%)。结论托吡酯添加治疗难治性癫疒间长期有效、安全,对部分性发作效果更佳。剂量个体化可使不良反应轻微和可耐受。

【Abstract】 Objective To investigate the efficacy and safety of Topiramate as adjunctive therapy in patients with refractory epilepsy.Methods 115 patients enrolled in this open-label,self-controlled prospective study which were designed to adopt slower dosage escalation schedule with lower initial,until reached target dosages(up to 8 weeks) or the most tolerable dosages of Topiramate,and maintained them 1~3 years treatment.The long-term efficacy,safety of Topiramate and their relationship with dosage were evaluated.Results The median percentages reduction were 56.0%,75.8%,76.1%,77.3% and 78.1% after 8 weeks,6 months,1 year,2 years and 3 years Topiramate treatment respectively for adults,and 32.1%,66.7%,68.9%,70.1% and 70.8% respectively for children.The overall efficacy for partial seizures(70.6%) was higher than that for generalized seizures(37.5%)((P<)0.05).Among them 10 patients(11.3%) achieved more than 2 years remission.The mean dosage in responders was(129.3±54.3) mg/d for adults and(3.1±1.4) mg/(kg·d) for children.Retention rates of Topiramate were 72.2%,62.5% and 56.1% after 1 year,2 years and 3 years,respectively.33 patients(28.7%) experienced adverse events.Most of the adverse events(24.3%) were found during titration period.The most common symptom of adverse events was anorexia(18.3%).6 patients(8.2%) had discontinued Topiramate for adverse events and 16 patients(21.9%) for inadequate controlled.Conclusions Topiramate is showed to be effective and safe for refractory epilepsy as adjunctive therapy in this long-term study,especially for partial seizures.Adverse events may be mild and well-tolerated when titration strategy is individual.

【关键词】 托吡酯癫癎有效性安全性
【Key words】 Topiramateepilepsyefficacysafety
  • 【文献出处】 临床神经病学杂志 ,Journal of Clinical Neurology , 编辑部邮箱 ,2006年06期
  • 【分类号】R742.1
  • 【被引频次】6
  • 【下载频次】91
节点文献中: 

本文链接的文献网络图示:

本文的引文网络